Pharmicell Co., Ltd.
Clinical trials sponsored by Pharmicell Co., Ltd., explained in plain language.
A biopharmaceutical company developing cell and gene therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Stem cell therapy for cirrhosis: Five-Year safety watch Results expected Dec 2026 (estimated)
-
Stem cells aim to restore sexual function after prostate cancer surgery
Disease control CompletedThis phase 2 trial tested a single injection of stem cells (from the patient's own bone marrow) into the penis to treat erectile dysfunction in men who had their prostate removed due to cancer. Fifty-four men participated. The study measured changes in erectile function scores us…
Phase 2 • Sponsor: Pharmicell Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Can your own stem cells repair heart attack damage?
Disease control CompletedThis study tested whether injecting a patient's own bone marrow stem cells into the heart's arteries could improve heart function after a heart attack. 90 adults with reduced heart pumping ability were randomly assigned to receive either stem cells plus standard care or standard …
Phase 3 • Sponsor: Pharmicell Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC